BioLife Solutions, Inc. $BLFS is Casdin Capital LLC’s 2nd Largest Position

Casdin Capital LLC cut its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,707,165 shares of the medical equipment provider’s stock after selling 1,000,000 shares during the quarter. BioLife Solutions comprises approximately 14.3% of Casdin Capital LLC’s portfolio, making the stock its 2nd biggest holding. Casdin Capital LLC owned approximately 13.93% of BioLife Solutions worth $171,100,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Hantz Financial Services Inc. grew its holdings in BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of BioLife Solutions by 82.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 1,994 shares during the period. Strs Ohio acquired a new stake in shares of BioLife Solutions in the first quarter worth approximately $153,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of BioLife Solutions by 547.9% in the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock worth $154,000 after acquiring an additional 6,032 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Karen A. Foster sold 96,923 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total transaction of $1,952,998.45. Following the completion of the sale, the insider directly owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. This represents a 46.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 990 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total value of $25,334.10. Following the completion of the sale, the chief financial officer owned 150,746 shares of the company’s stock, valued at approximately $3,857,590.14. This represents a 0.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 104,669 shares of company stock valued at $2,134,881. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $18.36 on Friday. The firm has a market capitalization of $886.79 million, a price-to-earnings ratio of -166.89 and a beta of 1.90. BioLife Solutions, Inc. has a one year low of $17.86 and a one year high of $29.62. The company’s 50 day moving average price is $22.81 and its 200 day moving average price is $24.84.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a report on Monday, December 29th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, January 21st. Northland Securities set a $34.00 price objective on BioLife Solutions in a report on Monday, January 5th. Finally, UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.